01
License
Split by field or by territory.
Medical Device · Intellectual Property
Invented in the treatment room. Built to hurt less.
Veripuremedi develops RF microneedling, pen needle, needle and cannula, and injector technology, and licenses it out. We don’t manufacture or sell devices — so we’re never competing with the company that does.
Where it starts
Less pain, without giving up the result.
Aesthetic results have improved for a decade. Pain hasn’t. When a patient doesn’t come back, it usually isn’t because the treatment failed. It’s because it hurt.
There have been two ways to fix that: more anesthetic, or less energy. One slows recovery. The other costs you the result. Neither is a trade a practitioner wants to make.
So we work on something else: how the needle enters, and how the energy is delivered. Every invention here started as a problem the founder ran into in his own practice.
What the portfolio covers
Five lines of work.
These are the subjects. The structures and the claims aren’t here yet — “Where it stands,” below, explains why.
-
20
RF microneedling — a new electrode structure, its control, its manufacture
Radio-frequency energy delivered into the skin through fine needles. Three lines of work: an electrode structure that departs from the ones in use today, the control that structure needs, and the processes that make it manufacturable at scale. The thickest part of the portfolio.
-
3
Pen needles and cartridges — less drug left behind
The needle and cartridge that load into a pen-type injector, aimed at the dose that stays behind after injection. The more a vial costs, the more that residue is money thrown away.
-
1
Needles and cannulas — a new structure
A new structure for the needle and cannula themselves. This is the part that actually meets tissue, where a small change in shape changes how it goes in.
-
1
Injectors — a low-pain algorithm for motorized injection
The device injects, not the hand. Past holding a steady rate, this covers the algorithm that shapes delivery so that it hurts less.
-
2
Cosmetic compositions
Two applications covering topical formulations themselves, not a device.
Where it stands
All 27 are patent pending.
27Patent applications · Korea
8Trademark applications
Korean applications publish 18 months after filing (Patent Act, Art. 64). Our earliest filing is March 2026, so the first publication lands in the second half of 2027, and the last of the 27 by the end of that year.
That’s the only reason this page stops at subjects. Nothing is being held back — until publication, these simply aren’t public documents. Sign an NDA and you get the specifications and drawings as filed.
Foreign filings are under review on the PCT route. We don’t announce dates for filings we haven’t made.
How the technology is offered
We license. We don’t manufacture.
Veripuremedi doesn’t manufacture or sell devices. The technology goes to the company best positioned to build it — which means we’re never across the table from our own licensee.
02
Assignment
Single application or full series.
03
Joint development
From prototype onward, when that works better for both sides.
How to start
Three steps.
01
Tell us the field
Tell us which of the five lines you’re after. We send a technical overview of everything that can be disclosed.
02
Non-disclosure agreement
Once an NDA is in place, you get the specifications and drawings for those applications.
03
Pick the structure
License, assignment, or joint development — we settle the structure and the terms together.
Contact
Let’s talk.
Technology inquiries go straight to the founder.